MaxCyte (NASDAQ: MXCT)
$4.73
(1.9%)
$0.09
Price as of May 9, 2024, 4:00 p.m. ET
MaxCyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MaxCyte Company Info
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
Valuation
Earnings Transcripts
MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript
MXCT earnings call for the period ending June 30, 2022.
Motley Fool Transcribing | Aug 11, 2022
MaxCyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript
MXCT earnings call for the period ending March 31, 2022.
Motley Fool Transcribing | May 10, 2022
MaxCyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript
MXCT earnings call for the period ending December 31, 2021.
Motley Fool Transcribing | Mar 22, 2022
MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript
MXCT earnings call for the period ending September 30, 2021.
Motley Fool Transcribing | Nov 12, 2021
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.